Arrowhead Pharmaceuticals to Present at Upcoming June 2018 Conferences
PASADENA, Calif.–(BUSINESS WIRE)–May 30, 2018–
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is
scheduled to make presentations at the following upcoming events:
Jefferies 2018 Global Healthcare Conference – New York, June 5-8,
2018
June 6, 3:30 p.m. EDT –Chris Anzalone, Ph.D., Arrowhead’s
president and chief executive officer, will present a corporate overview
41stEuropean Cystic Fibrosis Conference–
Belgrade, Serbia, June 6-9, 2018
June 6, 5:55 p.m. CET –Erik Bush, Ph.D., Arrowhead’s director of
extra-hepatic targeting, will deliver an oral presentation titled, “Targeting
αENaC with an epithelial RNAi trigger delivery platform for the
treatment of cystic fibrosis”
The Science of HBV Cure 2018 – Suntec City, Singapore, June 8-9,
2018
June 8, 5:30 p.m. SGT –Bruce Given, M.D., Arrowhead’s chief
operating officer and head of R&D, will deliver an oral presentation
titled, “Hitting HBV everywhere; why RNAi holds so much potential as
a platform therapy in CHB”
Global Hepatitis Summit 2018 – Toronto, June 14-17, 2018
June 15, 2:15 p.m. EDT –Christine Wooddell, Ph.D., Arrowhead’s
director of liver targeting, will deliver an oral presentation titled, “Interferon-gamma
pathway is activated in a chronically HBV infected chimpanzee that
controls HBV following ARC-520 RNAi treatment”
JMP Securities Life Sciences Conference– New York, June 20-21,
2018
June 20, 9:00 a.m. EDT –Bruce Given, M.D., will present a
corporate overview
27th Annual Alpha-1 National Education Conference– San
Francisco, June 29 – July 1, 2018
June 29, 3:45 p.m. PDT –Bruce Given, M.D., will deliver an oral
presentation titled, “Development of ARO-AAT, an RNAi based
therapeutic for Alpha-1 antitrypsin deficiency-related liver disease”
A copy of presentation materials may be accessed on the Events
and Presentations page under the Investors section of the Arrowhead
website after the presentations conclude.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable
diseases by silencing the genes that cause them. Using a broad portfolio
of RNA chemistries and efficient modes of delivery, Arrowhead therapies
trigger the RNA interference mechanism to induce rapid, deep, and
durable knockdown of target genes. RNA interference, or RNAi, is a
mechanism present in living cells that inhibits the expression of a
specific gene, thereby affecting the production of a specific protein.
Arrowhead’s RNAi-based therapeutics leverage this natural pathway of
gene silencing.
For more information, please visit www.arrowheadpharma.com,
or follow us on Twitter @ArrowheadPharma.
To be added to the Company’s email list and receive news directly,
please visit http://ir.arrowheadpharma.com/email-alerts.
Safe Harbor Statement under the Private Securities Litigation Reform
Act:
This news release contains forward-looking statements within the
meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our
current expectations and speak only as of the date hereof. Our actual
results may differ materially and adversely from those expressed in any
forward-looking statements as a result of various factors and
uncertainties, including the safety and efficacy of our product
candidates, the duration and impact of regulatory delays in our clinical
programs, our ability to finance our operations, the future success of
our scientific studies, our ability to successfully develop drug
candidates, the timing for starting and completing clinical trials,
rapid technological change in our markets, and the enforcement of our
intellectual property rights. Our most recent Annual Report on Form 10-K
and subsequent Quarterly Reports on Form 10-Q discuss some of the
important risk factors that may affect our business, results of
operations and financial condition. We assume no obligation to update or
revise forward-looking statements to reflect new events or circumstances.
Source: Arrowhead Pharmaceuticals, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180530005534/en/
Source: Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com
or
Investors
and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
britchie@lifesciadvisors.com
www.lifesciadvisors.com